Acute generalized exanthematous pustulosis induced by duloxetine-Reference-Cited by-同舟云学术

Acute generalized exanthematous pustulosis induced by duloxetine

Published:2023-03-25 Issue:2 Volume:2 Page:363-365
ISSN:2768-6566
Container-title:JEADV Clinical Practice
language:en
Short-container-title:JEADV Clinical Practice

Author:

Deydier Numa¹^ORCID,Jantzem Hélène²,Alavi Zarrin³,Le Flahec Glen⁴,Robert Marine¹^ORCID,Roguedas‐Contios Anne‐Marie¹,Brenaut Emilie¹^ORCID,Misery Laurent¹^ORCID,Gourier Greta²

Affiliation:

1. Dermatology and Venereology Department University Hospital of Brest Brest France

2. Regional Pharmacovigilance Center, University Hospital of Brest Brest France

3. Inserm, CIC 1412 University Hospital of Brest Brest France

4. Pathology Department University Hospital of Brest Brest France

Abstract

AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor. Some rare duloxetine‐induced hypersensitivity skin reactions have been reported. We report a case of acute generalized exanthematous pustulosis potentially induced by duloxetine. Skin pustules appeared 8 days after the introduction of duloxetine. Treatment with topical clobetasol propionate led to gradual remission of the lesions. As there are no cases of duloxetine‐induced acute generalized exanthematous pustulosis(AGEP) in the literature, we did a research in the World Health Organization (WHO) pharmacovigilance database (21 March 2022) and found three cases of duloxetine‐induced AGEP. The French causality assessment score for our case of duloxetine‐induced AGEP was 15 (C2S3). The Naranjo score was 7, indicating a possible correlation between AGEP and the use of duloxetine. This was consistent with the WHO causality score. We inform clinicians of the possibility of AGEP following therapy with duloxetine.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.138

Reference13 articles.

1. Résumé des caractéristiques du produit. DULOXETINE EG 60 mg gélule gastro‐résistante—Base de données publique des médicaments.https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66334292&typedoc=R(2022). Accessed 25 Mar 2022.

2. Drug Result Page. In‐depth answers—medication safety—adverse effects.https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=topHome&isToolPage=true(2022). Accessed 12 Sep 2022.

3. Acute generalized exanthematous pustulosis induced by amoxapine

4. Acute exanthematous pustulosis during amoxapine treatment;Larbre B;Ann Derm Venereol,1994

5. Acute Generalized Exanthematous Pustulosis with Photodistribution Pattern Induced by Sertraline